Tumor-infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma

WU Jianzhong; CHEN Lin; LIU Xiaoan; GAO Quangen; HUANG Weixian

doi:10.3971/j.issn.1000-8578.2015.11.012

Cancer Research on Prevention and Treatment > 2015 > 42(11): 1114-1118. > DOI: 10.3971/j.issn.1000-8578.2015.11.012

WU Jianzhong, CHEN Lin, LIU Xiaoan, GAO Quangen, HUANG Weixian. Tumor-infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(11): 1114-1118. DOI: 10.3971/j.issn.1000-8578.2015.11.012

Citation:

PDF (7748 KB)

Tumor-infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma

1. Department of General Surgery, The First People's Hospital of Wujiang Affiliated to Nantong University, Suzhou 215200, China; 2. Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

More Information

Received Date: January 18, 2015
Revised Date: March 16, 2015

Graphical Abstract

Abstract

Abstract

Objective To investigate the association between tumor-infiltrating lymphocytes and neoadjuvant chemotherapeutic effect in patients with breast carcinoma. Methods We retrospectively evaluated 59 female patients with breast carcinoma treated with neoadjuvant chemotherapy followed by definitive surgical resection in the First Affiliated Hospital of Nanjing Medical University from December, 2010 to November, 2013. By the method of tumor-infiltrating lymphocyte count score, we counted the total score of intratumoral lymphocytes and stromal lymphocytes before chemotherapy, as well as the stromal lymphocytes after the operation. The pathological responses were evaluated by Miller and Payne (MP) grading system criteria after the operation. Then the correlation between tumor-infiltrating lymphocytes and the pathological responses after the operation were investigated. Results The remission rate of neoadjuvant chemotherapy in the highpercentage tumor-infiltrating lymphocytes group(3-6 level) was more effective than that in the low-percentage group(0-2 level) (P=0.001). The higher stromal lymphocytes percentage after the neoadjuvant chemotherapy had the higher remission rate(P=0.031). Conclusion Tumor-infiltrating lymphocytes have strong correlation with pathological responses to chemotherapy and they would be the important parameters in predicting the remission rate of neoadjuvant chemotherapy.
- Breast carcinoma,
- Neoadjuvant chemotherapy,
- Tumor-infiltrating lymphocytes

FullText(HTML)

References (29)

References

[1]	Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer[J]. N Engl J Med, 20 05, 353(25): 2654-66.
[2]	DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response:crosstalk between adaptive and innate immune cells during breast cancer progression[J]. Breast Cancer Res, 2007, 9(4): 212.
[3]	Schmidt M, Böhm D, von Törne C, et al. Thehumoral immune system has a key prognostic impact in node-negative breast cancer[J]. Cancer Res, 2008, 68(13): 5405-13.
[4]	Zitvogel L, Kroemer G. The immune response against dying tumor cells: Avoid disaster, achieve cure[J]. Cell Death Differ, 2008, 15 (1): 1-2.
[5]	Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy[J]. Immunol Rev, 2007, 220: 47 -59.
[6]	Apetoh L, Tesniere A, Ghiringhelli F, et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies[J]. Cancer Res, 2008, 68(11): 4026-30.
[7]	Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy[J]. Nat Rev Immunol, 2008, 8(1): 59-73.
[8]	Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel[J]. J Clin Oncol, 2002, 20(6): 1456-66.
[9]	Fisher B, Bryant J, Wolmark N, et al. Effect of preoperativechemotherapy on the outcome of women with operable breast cancer[J]. J Clin Oncol, 1998, 16(8): 2672-85.
[10]	Black MM, Speer FD, Opler SR. Structural representations of tumor-host relationship in mammary carcinoma: Biologic and prognostic significance[J]. Am J Clin Pathol, 1956, 26(3): 250-65.
[11]	Denkert C, Loibl S, Noske A. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer[J]. J Clin Oncol, 2010, 28(1): 105-3.
[12]	Demaria S, Voim MD, Shapiro RL, et al. Development of tumorinfiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy[J].Clin Cancer Res, 2001, 7(10): 3025-30.
[13]	Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2012, 13 2(3): 793-805.
[14]	Feng G, Kang H, Zhang Y, et al. Histopathological changes of breast cancer after neoadjuvant chemotherapy[J]. Shandong Yi Yao, 2009, 49(40), 22-4. [冯根, 康骅, 张雁, 等. 乳腺癌新辅助化疗前后病理组织学的变化[J]. 山东医药, 2009, 49(40): 22-4.]
[15]	Rajan R, Esteva FJ, Symmam WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response[J]. Clin Breast Cancer, 2004, 5(3): 235-8.
[16]	Gong XY, Ding HY. Breast pathology[M]. Beijing: People’s Medical Publishing House, 2009: 506-7. [龚西騟, 丁华野. 乳腺病理学[M]. 北京: 人民卫生出版社, 2009: 506-7.]
[17]	Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26(5): 778-85.
[18]	Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: Indispensable for therapeutic success?[J]. J Clin Invest, 20 08, 118(6): 1991-2001.
[19]	Hornychova H, Melichar B, Tomsova M, et al. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma[J]. Cancer Invest, 2008, 26(10): 10 24-31.
[20]	Ge o rg i a n n o s SN, Re n a u t A, Go o d e AW, e t a l . Th e immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their associatin with prognostic indicators[J]. Surgery, 2003, 13 4(5): 827-34.
[21]	Leong PP, Mohammad R, Ibrahim N, et al. Phenotyping of lymphocytes expressing regulatory and effect or markers in infiltrating ductal carcinoma of the breast[J]. Immunol Lett, 2006, 10 2(2): 229-36.
[22]	Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma[J]. Cancer, 1996, 77(7): 1303-10.
[23]	Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer[J]. Cancer Res, 1998, 58(16): 3491-4.
[24]	Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up[J]. Cancer, 1977, 40(4): 1365-85.
[25]	Kuroda H, Tamaru J, Sakamoto G, et al. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast[J]. Virchows Arch, 2005, 446(1): 10-4.
[26]	Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes[J]. Clin Cancer Res, 2008, 14(16): 5158-65.
[27]	Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial[J]. J Clin Oncol, 2009, 27(8): 1168-76.
[28]	Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, (8): 2329-34.
[29]	Parshad R, Kapoor S, Gupta SD, et al. Does famotidine enhance tumor-infiltrating lymphocytes in breast cancer?[J]. Acta Oncol, 20 02, 41(4): 362-5.

[1]	TANG Wenchao, LI Yuanwei, CHEN Jia, QIN Yipeng, WU Zhiying, FU Huifeng. Prognostic Evaluation of Prognostic Nutrition Index for Patients with Radical Cystectomy: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 871-876. DOI: 10.3971/j.issn.1000-8578.2021.21.0326
[2]	WANG Yan, CAO Yu, YIN Jinhuan, LIU Junfeng. Correlation of Prognostic Nutritional Index with Overall Survival of Postoperative Patients with Thymoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(2): 140-144. DOI: 10.3971/j.issn.1000-8578.2021.20.0651
[3]	WEI Xueyan, HAN Guang, LI Ying, HU Desheng. Effect of Whole-course Nutrition Support on Nutritional Status of Patients with Locally Advanced Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(8): 617-622. DOI: 10.3971/j.issn.1000-8578.2020.20.0432
[4]	LIU Faqiang, LU Xiaolin, CHANG Yingbin. Clinical Effect of Oral Nutritional Supplements in Patients with Colorectal Cancer After Emergency Surgery[J]. Cancer Research on Prevention and Treatment, 2019, 46(7): 610-613. DOI: 10.3971/j.issn.1000-8578.2019.19.0529
[5]	HUANG Jing, SHEN Hongmei, WU Yunli. Effect of Modified Yangyin Qingfei Decoction Combined with Nutritional Intervention on Nutritional Status and Curative Effect of Nasopharyngeal Carcinoma Patients Undergoing Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2019, 46(2): 159-163. DOI: 10.3971/j.issn.1000-8578.2019.18.0814
[6]	QI Xiaoguang, QI Chunyan, QIN Boyu, WANG Lijie, HU Yi. Comparison of Different Time Nutritional Intervention on Chemotherapy-induced Ⅳ Degree Myelosuppression in Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(1): 29-31. DOI: 10.3971/j.issn.1000-8578.2018.17.0715
[7]	WEI Yujia, YAN Chao, SUN Kejuan, DU Hongzhen, LI Zengning. Nutritional Status of 427 Malignant Tumor Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(1): 19-23. DOI: 10.3971/j.issn.1000-8578.2018.17.0781
[8]	SUN Zhiwei, JIA Jun, YANG Ying, LIU Chuanling, XIAO Yanjie, YU Jing, ZHANG Xiaodong. Correlation of Baseline Nutritional Status with Response to Chemotherapy and Survival of Advanced Esophageal Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(9): 612-617. DOI: 10.3971/j.issn.1000-8578.2017.17.0158
[9]	ZHU Bu-dong, XUE De-liang, LIU Shu-jun, et al. The Evaluation of Nutritional Parameters in Patients with Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(03): 220-221. DOI: 10.3971/j.issn.1000-8578.2143
[10]	Liu-qing YANG, Han-ping SHI. The establishment and innovation of nutrition diagnosis and treatment System for cancer patients in China[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.20241268

Cited By

Get Citation

PDF

XML

Article views (1547) PDF downloads (956)

Turn off MathJax

Article Contents

Abstract

References

Tumor-infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Tumor-infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content